Merck Serono ditches cladribine, leaving MS franchise exposed
This article was originally published in Scrip
Merck Serono has finally given up on cladribine, its oral candidate for relapsing remitting multiple sclerosis. It has withdrawn the product from the approval process in the US and will cease to pursue approval everywhere else. It will also withdraw the product from sale in Russia and Australia, where it is marketed as Movectro.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.